Search
PGX-100
go.drugbank.com/drugs/DB06114InvestigationalIt is a nearly nonanticoagulant heparin derivative that retains its anti-inflammatory activity. … It is developed for treatment of exacerbation of obstructive pulmonary disease (COPD) and for the prevention and treatment of cardiac ischemia reperfusion injury (following acute myocardial infarction
IDD-3
go.drugbank.com/drugs/DB05427ExperimentalIt consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. … It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from the patient's own white blood cells.
Tetrafluoroborate
go.drugbank.com/drugs/DB16340InvestigationalTetrafluoroborate is under investigation in clinical trial NCT02907073 (Positron Emission Tomography (PET) Imaging Studies With NIS Reporter).
Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media
go.drugbank.com/drugs/DB15728ExperimentalOne of these companies, Aspire, has created their own product, ACT-20 Conditioned Medium as a product for testing. … The condition medium (CM) derived from these MSCs has also been implicated in therapeutic properties.
Influenza B virus B/Austria/1359417/2021 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB16923ApprovedInactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde. … This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes.
Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB18750ApprovedInactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde. … This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes.
Influenza A virus A/District of Columbia/27/2023 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB22669ApprovedInactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde. … This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes.
Influenza A virus A/Victoria/800/2024 CVR-289 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB22671ApprovedInactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde. … This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes.
Influenza A virus A/Perth/722/2024 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB31654ApprovedInactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde. … This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes.